Drug Profile
Diroximel fumarate - Alkermes/Biogen
Alternative Names: ALKS-8700; BIIB-098; VUMERITYLatest Information Update: 22 Nov 2023
Price :
$50
*
At a glance
- Originator Alkermes plc
- Developer Alkermes plc; Biogen
- Class Anti-inflammatories; Fumarates; Pyrrolidines; Small molecules
- Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Multiple sclerosis
Most Recent Events
- 11 Oct 2023 Updated efficacy data from a phase III EVOLVE-1 trial in Multiple sclerosis presented at 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis, 2023 (Joint ECTRIMS-ACTRIMS 2023)
- 22 Apr 2023 Updated adverse events data from a phase III EVOLVE-1 trial in Multiple sclerosis presented at the 75th Annual Meeting of the American Academy of Neurology (AAN-2023)
- 22 Apr 2023 Updated efficacy and adverse events data from a phase III EVOLVE-1 trial in Multiple sclerosis presented at the 75th Annual Meeting of the American Academy of Neurology (AAN-2023)